Recs

4

5 Stocks That Are Cheaper Than You Think

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Your expectations can use a refresh button.

The best thing about growth stocks is that they often grow into their seemingly outlandish valuations. As long as earnings continue to grow, good things will typically follow.

Things get even more interesting when bottom-line growth outpaces gains in share price. Over time, that's a winning recipe for any investor.

The term "next year's earnings" now refers to 2012, and you may be amazed at how quickly some of the market's seemingly overpriced players are growing. Loftier profit targets translate into lower forward P/E multiples.

Let's take a look at five unexpected cheapies.

Company

Close

This Year P/E

Next Year P/E

My Watchlist

OmniVision (Nasdaq: OVTI  ) $32.18 11 10 Add
NetSol (Nasdaq: NTWK  ) $1.35 7.5 7.5 Add
SouFun (Nasdaq: SFUN  ) $18.18 14 12 Add
Sonus Networks (Nasdaq: SONS  ) $3.00 150 43 Add
SIGA Technologies (Nasdaq: SIGA  ) $10.86 32 12 Add

Source: Yahoo! Finance.

Valuation is only a number
Many of these multiples -- even those clocking in for next year -- are chunky. You don't often hear something along the lines of "this stock is so cheap that it's trading for a mere 43 times next year's projected profitability."

Then again, there is more to this basket of presumably pricey stocks than meets the cynical eye.

OmniVision Technologies makes image sensors. How big is this market? Well, have you seen a smartphone that didn't come with a snazzy camera? Let's think about portable media players and tablets. The first iPad didn't even have a camera when it was introduced last year. The iPad 2 comes with two. There was a time when iPods were just for music, but now the more popular lines come with the ability to snap digital photographs. Omnivision's sitting pretty, with an attractive forward earnings multiple in the pre-teens to boot.

NetSol Technologies provides leasing software and other enterprise solutions. Despite its smallish size, NetSol is every inch a global player. It inked sizable automotive-related deals in Japan and India last month.

NetSol boosted its guidance a few weeks ago for its fiscal year which ends this month. Instead of earning $0.15 a share to $0.20 a share, NetSol now sees a profit of $0.18 a share to $0.23 a share. This doesn't seem like the kind of stock that deserves a Dollar Menu price.

SouFun was such a hot IPO in 2010 that the Chinese website operator declared a 4-for-1 stock split earlier this year. Investors are shying away from China's dot-com speedsters these days, but it's easy to fall for SouFun trading at a sharp discount to its growth rate. The company's real estate data may seem iffy given China's real estate bubble, but its popular portal for home furnishings and decor should continue to do well in a robust economy.

Sonus Networks outfits the IP networking market with media and signaling gateways, policy/routing servers, session border controllers, and subscriber feature servers. Sonus has posted losses in two of the past three quarters, but skies should get clearer from here. Few will argue that Sonus is cheap at a negative trailing earnings multiple or even 43 times next year's target, but it's working its way out of depressed levels.

SIGA Technologies took off after the biotech was selected for procurement of its smallpox antiviral for the Strategic National Stockpile. Investors may have their doubts about what SIGA will do for an encore, though it does look cheap at just 12 times next year's forecast bottom line of $0.91 a share.

Adding it up
None of these stocks are immune to a market meltdown. If you're looking for bulwarks, you'll have to find them somewhere else.

These investments are largely high-beta growth stocks, and will likely remain that way for several more years. The key here, though, is that they aren't as expensive as pundits make them out to be.

It's the opportunity that you didn't know that you were waiting for.

Interested in reading more about any of these stocks? Add them to My Watchlist to find all of our Foolish analysis. And if you like these five stocks, check out the six stocks that Tom and David Gardner think you should be watching in a free special report.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Longtime Fool contributor Rick Munarriz also believes that expensive stocks can get even more expensive, too. He does not own shares in any of the stocks in this story. He is part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 15, 2011, at 12:34 PM, Superpalatial wrote:

    "Investors may have their doubts about what SIGA will do for an encore"

    Well, let's see. Maybe sell their perfectly effective, no-side-effect smallpox antiviral to any country concerned with bioterrorism for example.

    And sell it for use as an adjunct to any sort of vaccine, since it's shown to be beautifully effective for nasty cases of vaccinia (and there's a new crop of cutting edge vaccines in final testing).

    And sell it for stockpiling in the event of cowpox or monkeypox pandemic (it's useful for most varieties of pox, including weaponized).

    And develop their pipeline, which includes candidates for dengue, lassa, and tons more.

    And sell more to the US gov, which in this one contract is only stockpiling enough for first responders.

    And tons more nerdier opportunities and applications I won't bore everyone with.

    So....nice diligence, dude. "Fool", indeed.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1507613, ~/Articles/ArticleHandler.aspx, 5/26/2012 9:06:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
SIGA $2.40 Down -0.06 -2.44%
SIGA Technologies,… CAPS Rating: **
SONS $2.41 Up +0.05 +2.12%
Sonus Networks, In… CAPS Rating: ****
NTWK $0.49 Up +0.01 +1.04%
NetSol Technologie… CAPS Rating: **
OVTI $14.19 Down -0.16 -1.11%
OmniVision Technol… CAPS Rating: ****

Advertisement